ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Long-Term control of rare autoimmune disease
Disease control Recruiting nowThis study aims to understand the long-term safety and effectiveness of avacopan, a medication for ANCA-associated vasculitis—a serious autoimmune condition that causes blood vessel inflammation. The trial will follow 300 adults with this condition for up to 5 years to monitor si…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Early trial tests 'Living Drug' for tough autoimmune illnesses
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy called NKX019 in people with severe autoimmune diseases like systemic sclerosis, inflammatory muscle disease, and certain types of vasculitis. The main goals are to find a safe dose and see if the treatment is tolerable…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC